SCHILKE TOBIN (CFO) sold 4.6% of their position (9.36K shares) of REVANCE THERAPEUTICS, INC. on the open market
Open‑market sale worth $47.2K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 3/19/2024ACC: 0001479290-24-000066
Officer· CFO
Since Nov 2018
-13.18K
Net shares
Net seller
$67.5K
Total sold
1
Open market trades
0B · 1S
2
Total transactions
13.18K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
−3.82K
Price / share
$5.30
Trade value
$20.28K
% of position
1.9%
3/15/2024
205.85K→202.03K
Common Stock
Direct
Shares
−9.36K
Price / share
$5.04
Trade value
$47.20K
% of position
4.6%
3/18/2024
202.03K→192.67K
Total
Net shares
−13.18K
Net value
-$67.48K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/15/2024 | F · Tax Withholding | −3.82K | $5.30 | $20.28K | 1.9% | 205.85K | 202.03K |
| Common Stock Direct | 3/18/2024 | S · Sale | −9.36K | $5.04 | $47.20K | 4.6% | 202.03K | 192.67K |
| Total | −13.18K | -$67.48K | ||||||
Derivative Transactions0
No derivative transactions reported